Bert O'Neil

Summary

Affiliation: University of North Carolina
Country: USA

Publications

  1. pmc Phospho-ERK and AKT status, but not KRAS mutation status, are associated with outcomes in rectal cancer treated with chemoradiotherapy
    Janine M Davies
    Department of Medicine, Division of Hematology Oncology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599 7305, USA
    Radiat Oncol 6:114. 2011
  2. doi request reprint Hepatocellular carcinoma: the role of the North American GI Steering Committee Hepatobiliary Task Force and the advent of effective drug therapy
    BERT H O'NEIL
    University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC 27599, USA
    Oncologist 12:1425-32. 2007
  3. ncbi request reprint Chemotherapy for advanced colorectal cancer: let's not forget how we got here (until we really can)
    BERT H O'NEIL
    UNC Lineberger Comprehensive Cancer Center, 3009 Old Clinic Building, CB 7305, Chapel Hill, NC 27599 7305, USA
    Semin Oncol 32:35-42. 2005
  4. doi request reprint Current options for the management of rectal cancer
    BERT H O'NEIL
    UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC 27599, USA
    Curr Treat Options Oncol 8:331-8. 2007
  5. ncbi request reprint High incidence of cetuximab-related infusion reactions in Tennessee and North Carolina and the association with atopic history
    BERT H O'NEIL
    University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC 27599, USA
    J Clin Oncol 25:3644-8. 2007
  6. doi request reprint Innovations in chemotherapy for metastatic colorectal cancer: an update of recent clinical trials
    BERT H O'NEIL
    Division of Hematology and Oncology, UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina 27599 7305, USA
    Oncologist 13:1074-83. 2008
  7. ncbi request reprint Gemcitabine radiosensitization for rectal cancer: step forward or dance step?
    BERT H O'NEIL
    Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
    Cancer J 11:110-2. 2005
  8. doi request reprint Peritoneal carcinomatosis of gastrointestinal origin: natural history and treatment options
    Janine Marie Davies
    University of North Carolina, Division of Hematology Oncology, 170 Manning Dr, CB 7305, Chapel Hill, NC 27599, USA
    Expert Opin Investig Drugs 18:913-9. 2009
  9. pmc Phase II study of the mitogen-activated protein kinase 1/2 inhibitor selumetinib in patients with advanced hepatocellular carcinoma
    BERT H O'NEIL
    University of North Carolina, 170 Manning Drive, Chapel Hill, NC 27599 730, USA
    J Clin Oncol 29:2350-6. 2011
  10. ncbi request reprint Expression of nuclear factor-kappaB family proteins in hepatocellular carcinomas
    BERT H O'NEIL
    Department of Medicine, Division of Hematology and Oncology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
    Oncology 72:97-104. 2007

Research Grants

Collaborators

Detail Information

Publications43

  1. pmc Phospho-ERK and AKT status, but not KRAS mutation status, are associated with outcomes in rectal cancer treated with chemoradiotherapy
    Janine M Davies
    Department of Medicine, Division of Hematology Oncology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599 7305, USA
    Radiat Oncol 6:114. 2011
    ..Our objective was to explore the relationships of KRAS and BRAF mutation status with p-AKT and p-ERK and outcomes in RC...
  2. doi request reprint Hepatocellular carcinoma: the role of the North American GI Steering Committee Hepatobiliary Task Force and the advent of effective drug therapy
    BERT H O'NEIL
    University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC 27599, USA
    Oncologist 12:1425-32. 2007
    ..This article briefly discusses the management of earlier stage HCC, then focuses on newer agents with promise, particularly sorafenib, a drug that appears to be the new standard of care for advanced disease...
  3. ncbi request reprint Chemotherapy for advanced colorectal cancer: let's not forget how we got here (until we really can)
    BERT H O'NEIL
    UNC Lineberger Comprehensive Cancer Center, 3009 Old Clinic Building, CB 7305, Chapel Hill, NC 27599 7305, USA
    Semin Oncol 32:35-42. 2005
    ..Chemotherapy is likely to remain a central element of the treatment strategy. Our understanding of its current role is discussed in this article...
  4. doi request reprint Current options for the management of rectal cancer
    BERT H O'NEIL
    UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC 27599, USA
    Curr Treat Options Oncol 8:331-8. 2007
    ....
  5. ncbi request reprint High incidence of cetuximab-related infusion reactions in Tennessee and North Carolina and the association with atopic history
    BERT H O'NEIL
    University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC 27599, USA
    J Clin Oncol 25:3644-8. 2007
    ....
  6. doi request reprint Innovations in chemotherapy for metastatic colorectal cancer: an update of recent clinical trials
    BERT H O'NEIL
    Division of Hematology and Oncology, UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina 27599 7305, USA
    Oncologist 13:1074-83. 2008
    ..Recent innovations in chemotherapy for mCRC are reviewed, with a focus on emerging data that may significantly improve both survival and quality of life for patients with CRC in the future...
  7. ncbi request reprint Gemcitabine radiosensitization for rectal cancer: step forward or dance step?
    BERT H O'NEIL
    Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
    Cancer J 11:110-2. 2005
  8. doi request reprint Peritoneal carcinomatosis of gastrointestinal origin: natural history and treatment options
    Janine Marie Davies
    University of North Carolina, Division of Hematology Oncology, 170 Manning Dr, CB 7305, Chapel Hill, NC 27599, USA
    Expert Opin Investig Drugs 18:913-9. 2009
    ....
  9. pmc Phase II study of the mitogen-activated protein kinase 1/2 inhibitor selumetinib in patients with advanced hepatocellular carcinoma
    BERT H O'NEIL
    University of North Carolina, 170 Manning Drive, Chapel Hill, NC 27599 730, USA
    J Clin Oncol 29:2350-6. 2011
    ..CONCLUSION In this study of selumetinib for patients with HCC, no radiographic responses were seen and time to progression was short, which suggests minimal single-agent activity despite evidence of suppression of target activation...
  10. ncbi request reprint Expression of nuclear factor-kappaB family proteins in hepatocellular carcinomas
    BERT H O'NEIL
    Department of Medicine, Division of Hematology and Oncology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
    Oncology 72:97-104. 2007
    ..Recent information has implicated IkappaB family members (e.g. Bcl-3) as possible mediators of NF-kappaB activation. Therefore, we examined the expression of all NF-kappaB family members and downstream targets in HCC...
  11. pmc Phase I trial of vinflunine and pemetrexed in refractory solid tumors
    Hanna K Sanoff
    Department of Medicine, Division of Hematology Oncology, School of Medicine, The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
    Invest New Drugs 29:131-6. 2011
    ..Pemetrexed has at least additive activity with other vincas. A phase I trial was undertaken to assess the safety of vinflunine and pemetrexed in patients with refractory solid tumors...
  12. pmc Antiangiogenic therapies for advanced hepatocellular carcinoma
    Keeran R Sampat
    Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina 27599, USA
    Oncologist 18:430-8. 2013
    ..Because of the anticipation of eventual resistance to anti-VEGF therapies, drugs that also target alternative proangiogenic pathways are being investigated. Recent clinical and preclinical data along with ongoing studies are reviewed...
  13. ncbi request reprint The proteasome as a target for cancer therapy
    Peter M Voorhees
    The Lineberger Comprehensive Cancer Center, Division of Hematology Oncology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599 7295, USA
    Clin Cancer Res 9:6316-25. 2003
    ..Below we discuss the rationale behind targeting the proteasome for cancer therapy, and review the preclinical and clinical data on proteasome inhibitors alone, and in combination with conventional chemotherapeutics...
  14. ncbi request reprint Targeted therapies for hepatocellular carcinoma
    Matthew R Skelton
    Division of Hematology and Oncology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
    Clin Adv Hematol Oncol 6:209-18. 2008
    ..Here we review recent and ongoing studies of new therapeutic agents for HCC, including the small-molecule tyrosine kinase inhibitors, monoclonal antibodies, and combinations of these drugs...
  15. pmc A Phase II Study of Long-Acting Octreotide in Patients With Advanced Hepatocellular Carcinoma and CLIP Score of 3 or Higher
    Usman Shah
    Division of Medical Oncology, University of North Carolina, Chapel Hill, NC
    Gastrointest Cancer Res 3:45-8. 2009
    ....
  16. ncbi request reprint Targeted therapy in colorectal cancer
    Supriya Rajpal
    University of California, San Francisco, Division of Hematology Oncology, 505 Parnassus Avenue, Box 1270, San Francisco, CA 94143 1270, USA
    Clin Adv Hematol Oncol 4:124-32. 2006
    ..Further advances in the treatment of CRC are expected through continued scientific investigation and well-designed clinical trials...
  17. ncbi request reprint Epidermal growth factor receptor-targeted treatment for advanced colorectal carcinoma
    Alan P Venook
    Department of Medicine, University of California San Francisco, San Francisco, California 94115, USA
    Cancer 103:2435-46. 2005
    ..Numerous molecules targeting the epidermal growth factor receptor have been investigated as therapeutic agents and appear to herald a shift in the treatment paradigm for colorectal carcinoma...
  18. doi request reprint Phase II study of bortezomib in patients with previously treated advanced urothelial tract transitional cell carcinoma: CALGB 90207
    J E Rosenberg
    Division of Hematology and Oncology, University of California, San Francisco Cancer Center, San Francisco, CA 94115, USA
    Ann Oncol 19:946-50. 2008
    ..Response rates to second-line chemotherapy for advanced UC are low and response duration is short. Bortezomib is a proteasome inhibitor with preclinical activity against UC...
  19. ncbi request reprint Cetuximab in the treatment of colorectal cancer
    Richard M Goldberg
    Division of Hematology Oncology, University of North Carolina, Chapell Hill, NC, USA
    Clin Adv Hematol Oncol 2:1-10; quiz 11-12. 2004
  20. ncbi request reprint A phase II study of fixed-dose rate gemcitabine plus low-dose cisplatin followed by consolidative chemoradiation for locally advanced pancreatic cancer
    Andrew H Ko
    Division of Hematology Oncology, University of California at San Francisco, San Francisco, CA 94115, USA
    Int J Radiat Oncol Biol Phys 68:809-16. 2007
    ..We conducted a Phase II nonrandomized trial to evaluate sequential chemotherapy followed by chemoradiation in this patient population...
  21. ncbi request reprint Rectal cancer radiotherapy
    Shelileah Ramsey
    Department of Radiation Oncology, University of North Carolina School of Medicine, UNC Lineberger Clinical Cancer Center, Chapel Hill, NC 27599 7512, USA
    Cancer J 13:204-9. 2007
    ....
  22. ncbi request reprint Complications associated with neoadjuvant radiotherapy in the multidisciplinary treatment of retroperitoneal sarcomas
    Abigail S Caudle
    Department of Surgery, Division of Surgical Oncology, University of North Carolina School of Medicine, 3010 Old Clinic Building, CB 7213, Chapel Hill, NC 27599, USA
    Ann Surg Oncol 14:577-82. 2007
    ..Preoperative RT offers theoretical advantages in the multidisciplinary care of RPS. The purpose of our study was to evaluate our experience using preoperative radiotherapy (PRT) in the treatment of RPS...
  23. ncbi request reprint Cancer and leukemia group B gastrointestinal cancer committee
    Richard M Goldberg
    University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA
    Clin Cancer Res 12:3589s-95s. 2006
    ..Future efforts aim to evolve new standards of care, evaluate new therapies, and answer relevant biological questions in gastrointestinal cancer...
  24. ncbi request reprint Impact of hospital procedure volume on surgical operation and long-term outcomes in high-risk curatively resected rectal cancer: findings from the Intergroup 0114 Study
    Jeffrey A Meyerhardt
    Dana Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA
    J Clin Oncol 22:166-74. 2004
    ..However, because these studies often lack detailed information on tumor and treatment characteristics as well as cancer recurrence, the true nature of this relation remains uncertain...
  25. ncbi request reprint Phase I/II study of preoperative oxaliplatin, fluorouracil, and external-beam radiation therapy in patients with locally advanced rectal cancer: Cancer and Leukemia Group B 89901
    David P Ryan
    Massachusetts General Hospital Cancer Center, Boston MA 02114, USA
    J Clin Oncol 24:2557-62. 2006
    ..This phase I/II study evaluated the addition of weekly oxaliplatin to preoperative continuous infusion fluorouracil (FU) and external-beam radiation therapy (RT) in patients with locally advanced rectal adenocarcinoma...
  26. ncbi request reprint Dose optimization via index-dose gradient minimization
    Sha X Chang
    Department of Radiation Oncology, University of North Carolina at Chapel Hill, 27599 7512, USA
    Med Phys 29:1130-46. 2002
    ..The primary advantages of our optimization algorithm include computational efficiency, intensity modulation selection choice, and performance reliability for a wide range of clinical beam setups and optimization objectives...
  27. ncbi request reprint Impact of T and N substage on survival and disease relapse in adjuvant rectal cancer: a pooled analysis
    Leonard L Gunderson
    Department of Radiation Oncology, Mayo Clinic Scottsdale, Scottsdale, AZ 85259, USA
    Int J Radiat Oncol Biol Phys 54:386-96. 2002
    ..To determine the rates of survival and disease control by TNM and MAC stage in three randomized North American rectal adjuvant studies...
  28. ncbi request reprint Impact of body mass index on outcomes and treatment-related toxicity in patients with stage II and III rectal cancer: findings from Intergroup Trial 0114
    Jeffrey A Meyerhardt
    Department of Medical Oncology, Dana Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA
    J Clin Oncol 22:648-57. 2004
    ..To study the relationship between body mass index (BMI) and rates of sphincter-preserving operations, overall survival, cancer recurrence, and treatment-related toxicities in patients with rectal cancer...
  29. ncbi request reprint Impact of T and N stage and treatment on survival and relapse in adjuvant rectal cancer: a pooled analysis
    Leonard L Gunderson
    Radiation Oncology Department, Mayo Clinic Cancer Center, Scottsdale, AZ 85259, USA
    J Clin Oncol 22:1785-96. 2004
    ..To determine survival and relapse rates by T and N stage and treatment method in five randomized phase III North American rectal adjuvant studies...
  30. ncbi request reprint Patient selection, realism, and randomized clinical trials
    Joel E Tepper
    J Clin Oncol 22:3215-7. 2004
  31. ncbi request reprint Staging of colorectal cancer: past, present, and future
    Janet K Horton
    Department of Radiation Oncology, University of North Carolina, Chapel Hill 27599, USA
    Clin Colorectal Cancer 4:302-12. 2005
    ..Staging in the future is likely to be a complicated combination of anatomic and biologic markers used together in mathematic modeling to group patients into prognostic risk groups, which can be used to guide tailored therapy...
  32. ncbi request reprint Impact of preoperative radiation for rectal cancer on subsequent lymph node evaluation: a population-based analysis
    Nancy N Baxter
    Department of Surgery, University of Minnesota, Minneapolis, MN 55455, USA
    Int J Radiat Oncol Biol Phys 61:426-31. 2005
    ..To determine the impact of preoperative radiotherapy (RT) on the accuracy of lymph node staging (LNS). Preoperative RT is a well-established component of rectal cancer treatment but its impact on LNS is unknown...
  33. ncbi request reprint An embarrassment of riches: neoadjuvant therapy of rectal cancer
    Joel E Tepper
    J Clin Oncol 23:1339-41. 2005
  34. ncbi request reprint In vivo intraoperative radiotherapy: a novel approach to radiotherapy for early stage breast cancer
    Karyn B Stitzenberg
    Department of Surgery, University of North Carolina, Chapel Hill, NC, USA
    Ann Surg Oncol 14:1515-6. 2007
    ..We are investigating the feasibility of partial breast irradiation using a single fraction of IORT delivered to the tumor in vivo prior to surgical resection...
  35. ncbi request reprint Evidence-based review of three-dimensional conformal radiotherapy for localized prostate cancer: an ASTRO outcomes initiative
    David E Morris
    Department of Radiation Oncology, University of North Carolina, Chapel Hill, NC 27514, USA
    Int J Radiat Oncol Biol Phys 62:3-19. 2005
    ....
  36. ncbi request reprint Radiation treatment parameters in the adjuvant postoperative therapy of gastric cancer
    Joel E Tepper
    Department of Radiation Oncology, University of North Carolina School of Medicine, Chapel Hill, NC 27599, USA
    Semin Radiat Oncol 12:187-95. 2002
    ..These should be used as guides for defining appropriate field arrangements for the adjuvant postoperative therapy of gastric cancer...
  37. ncbi request reprint Rectal cancer: can we throw away the scalpel?
    Michael O Meyers
    Ann Surg Oncol 12:95-7. 2005
  38. ncbi request reprint ASTRO 45th annual meeting presidential address: Medicine's arrow, medicine's cycle: lessons for radiation oncology
    Joel E Tepper
    Int J Radiat Oncol Biol Phys 59:623-33. 2004
  39. ncbi request reprint Cancer and leukemia group B (CALGB) 89805: phase II chemoradiation trial using gemcitabine in patients with locoregional adenocarcinoma of the pancreas
    A William Blackstock
    Radiation Oncology, Wake Forest University Comprehensive Cancer Center, Winston Salem, NC 277516, USA
    Int J Gastrointest Cancer 34:107-16. 2003
    ..Determine the safety and efficacy of twice weekly gemcitabine and concurrent radiation to the upper abdomen followed by weekly gemcitabine in patients with surgically staged, locally advanced pancreatic cancer...
  40. ncbi request reprint Risk of pelvic fractures in older women following pelvic irradiation
    Nancy N Baxter
    Division of Colon and Rectal Surgery, Department of Surgery, University of Minnesota, Minneapolis 55455, USA
    JAMA 294:2587-93. 2005
    ..Pelvic fractures, including hip fractures, are a major source of morbidity and mortality in older women. Although therapeutic pelvic irradiation could increase the risk of such fractures, this effect has not been studied...
  41. ncbi request reprint Is less more? Lessons in radiation schedules in breast cancer
    Carolyn I Sartor
    J Natl Cancer Inst 94:1114-5. 2002
  42. ncbi request reprint Increased risk of rectal cancer after prostate radiation: a population-based study
    Nancy N Baxter
    Department of Surgery, University of Minnesota Medical School, Minneapolis, Minnesota 55455, USA
    Gastroenterology 128:819-24. 2005
    ..Radiation therapy for prostate cancer has been associated with an increased rate of pelvic malignancies, particularly bladder cancer. The association between radiation therapy and colorectal cancer has not been established...
  43. pmc Postoperative irradiation for rectal cancer increases the risk of small bowel obstruction after surgery
    Nancy N Baxter
    Department of Surgery, St Michael s Hospital, University of Toronto, Toronto, Ontario, Canada
    Ann Surg 245:553-9. 2007
    ..To determine the risk of small bowel obstruction (SBO) after irradiation (RT) for rectal cancer..

Research Grants2

  1. Radiation-induced signaling and treatment resistance
    BERT O NEIL; Fiscal Year: 2007
    ..The long-term goal of our research is to apply drugs that target tumor but not normal tissue in addition to radiation to improve the effectiveness of radiation on rectal cancer. ..